Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 551 - 560 of 785 studies

Oral and Gastrointestinal

Master Protocol: A Phase 1b, non-randomized, open-label, repeat-dose, single center study utilizing a master protocol to investigate the safety and tolerability of multiple study interventions in advanced therapy naïve participants with moderate to severe ulcerative colitis. Sub Protocol: A Phase 1b, non-randomized, open-label, repeat-dose, single center study to investigate the safety and tolerability of aletekitug in advanced therapy naïve participants with moderate to severe ulcerative colitis. (PEGASUS)

Metabolic and Endocrine

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed with Type 1 Diabetes Aged ≥1 to <36 Years (BARICADE-PRESERVE) (I4V-MC-JAJK (BARICADE-PRESERVE))

Inflammatory and immune system

A single-arm, open-label, multi-centre, phase I/II first-in-human study evaluating the safety and clinical activity of QEL-005, an autologous CAR T-regulatory cell therapy treatment targeting CD19, in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA) (CHILL (QEL-005-CLN-01))

Cancer and neoplasms

CA266-0004: A Randomized Phase 2/3 Study of BMS-986545-01 (BNT327) in Combination with Chemotherapy Versus Standard of Care in Previously Untreated Participants with Unresectable, Metastatic, or Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Cancer and neoplasms

A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC whose tumor PD-L1 status is considered negative (BNT327-05 (ROSETTA-Breast 01))

Metabolic and Endocrine

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D). (SAB-142-201(SAFEGUARD))

Respiratory

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab adjunctive therapy in adult participants with COPD with type 2 inflammation characterized by an eosinophilic phenotype (ENDURA-2)

Cardiovascular

A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy. | KINSHIP-DCM (DAN-301 (KINSHIP-DCM))

Congenital disorders

A Phase 2, Open-label, Basket Study Investigating the Safety and Efficacy of GTX-102 in Adult and Pediatric Subjects with Deletion- or Nondeletion-type Angelman Syndrome (GTX-102-CL210)

A Global Multi-Center Prospective Observational Cohort to Support Drug Development in Adult Patients with Primary Sclerosing Cholangitis (WIND-PSC Study) (WIND-PSC)